D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. The company offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; DWR-2206, a regenerative medicine cell-product for bullous keratopathy; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM, ALC, ERM, and PVR membrane staining. It is also developing DW-5LBT, a lidocaine patch for neuropathic pain after shingles; K-321 to treat fuch endothelial corneal dystrophy which is in Phase III clinical trials; and H-1337, a multi-kinase inhibitor that has started Phase IIb clinical trials for the treatment of glaucoma/ocular hypertension. The company was founded in 1999 and is headquartered in Nagoya, Japan.
तुलना करने के लिए मीट्रिक्स | 4576 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध4576पीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −4.2x | −5.2x | −0.6x | |
PEG अनुपात | 0.09 | −0.13 | 0.00 | |
क़ीमत/बुक | 7.4x | 4.1x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 11.6x | 75.7x | 3.1x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 43.5% | 52.8% | |
उचित मूल्य अपसाइड | अनलॉक करें | 4.9% | 8.4% | अनलॉक करें |